Thus, an overexpression of this proto-oncogene may be a surrogate marker for TP53 pathway inactivation, which is often associated with alterations common in aggressive urothelial carcinoma and correlates with the poor outcome of basal and luminal MIBC as described in recent studies [7, 16, 48, 49]. Here, TP53 is linked to urothelial carcinoma.